about
Pleiotropic effects of statins in the diseases of the liverHepatic hemodynamic changes during liver transplantation: a reviewPrevention of portal hypertension: from variceal development to clinical decompensationFeasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertensionLiver cirrhosisSpironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat.Management of cirrhotic ascitesGamna-Gandy bodies of the spleen detected with susceptibility weighted imaging: maybe a new potential non-invasive marker of esophageal varices.Animal models of portal hypertensionAbnormal splenic artery diameter/hepatic artery diameter ratio in cirrhosis-induced portal hypertension.Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats.Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.Portal hypertension: diagnosis and management with particular reference to variceal hemorrhage.Physiopathology of splanchnic vasodilation in portal hypertension.Complications of cirrhosis. A 50 years flashback.Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension.Intestinal permeability in rats with CCl4-induced portal hypertension.Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats.Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.Testing beneficial therapy in human cirrhosis using animal models of cirrhosis.Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension.Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.Review article: the role of the microcirculation in liver cirrhosis.Lack of a correlation between portal vein flow and pressure: toward a shared interpretation of hemodynamic stress governing inflow modulation in liver transplantation.The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complicationsInsulin resistance in patients with cirrhosis and portal hypertension
P2860
Q26741176-5C1E513C-B9C6-4720-8DC7-448C450EA2E3Q26822255-3D3F9DA1-37B3-4FF8-BF24-0E77298DBF7CQ26865665-0C01E0CA-E943-42E4-AE1B-DDA35D1C5F6AQ30481806-8D963C83-0D3D-4135-9A60-F2C2F3BD7422Q34010340-F7DF54AD-B74D-4EB7-988F-20F05D88343FQ34222291-AB9CB342-2598-445E-BEBC-B64B92AF7523Q34475601-AADABBE2-191B-4295-BD99-D219C12209E9Q34576828-BC93CA84-DB49-402C-91E3-065667D00F12Q36640036-CD0D5316-41DB-47C5-97DD-A7DC147A83DDQ36654502-687D3E32-092A-41D0-A3A6-D8479ADD9DD2Q37296246-49AFE239-C3FE-4A2A-B8D3-486E93AEB2FAQ37362862-1EB47E0D-AA77-4D30-BA5C-43272F856A0CQ37363773-549E0D20-33DC-488F-9A25-3D8783275A38Q37811073-CA58C753-709D-4939-9EB3-94A525EB1E06Q37821307-F24FB087-1930-47A6-8C18-257021E41CA1Q38424360-55E45C6B-C2FE-4287-B1C8-57DC036895D2Q38446357-8678D160-EAAD-4A29-A542-4264B1A5FC08Q38831994-CEF36121-9751-4282-93F0-568BB354B757Q38905396-A3C2C040-913D-4E3A-8E2B-9DB2EB0E3BAEQ40094604-01C52994-E2D8-4B30-BE06-14D25909C38AQ40974160-A97CD882-9D57-4023-A079-B5F036DBADC6Q41416491-5DFA50A9-BC7A-448E-99F5-F8EFB9475B37Q42555733-DCA5CA19-47AA-4152-82A2-93991DAD0957Q42667685-3E44390B-1AEF-4F30-8CCD-4D43D95CED3CQ42699745-828FA1B0-1F0F-4407-A3F3-C90F5EB17435Q43288624-4D05EFD4-4561-4192-B9F1-1CFBCFE89650Q44582406-0D469134-1B73-42F4-B9D3-B8BE14FD27A8Q47812599-7691673A-77AE-42F2-9D9D-EFA75550A2E0Q49069784-CD9D59C7-8D76-4F3A-81A3-8D2C86741029Q54342105-E075B289-01FC-4A59-9F58-D5F3AE3001E8Q58765012-A7D3ADFD-8D9A-4AD6-AA97-5A9D2147E97AQ59288256-C53E9652-B33E-4F12-8916-0C8603CAA547
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Portal hypertension: from bedside to bench.
@ast
Portal hypertension: from bedside to bench.
@en
type
label
Portal hypertension: from bedside to bench.
@ast
Portal hypertension: from bedside to bench.
@en
prefLabel
Portal hypertension: from bedside to bench.
@ast
Portal hypertension: from bedside to bench.
@en
P1476
Portal hypertension: from bedside to bench
@en
P2093
Roberto J Groszmann
P304
P356
10.1097/01.MCG.0000155552.14396.3D
P433
P577
2005-04-01T00:00:00Z